Efficacy and Safety of Epicutaneous Immunotherapy for Peanut Allergy in Subjects With and Without Atopic Dermatitis

In the pooled Phase 3, randomized, double-blind, placebo-controlled trials (P3PCT), PEPITES and REALISE, peanut-allergic children aged 4-11 years were treated with daily epicutaneous immunotherapy (EPIT) with a 250- μg peanut patch (VP250) or placebo (PBO). PEPITES assessed EPIT safety and efficacy, while REALISE assessed EPIT safety without requiring food challenges. It is important to establish whether underlying skin disease affects the safety or efficacy profiles of EPIT. (Source: Journal of Allergy and Clinical Immunology)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://bit.ly/2TAjYlq